Daisuke Yoshinaga, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 5 | 2022 | 1629 | 1.010 |
Why?
|
| Induced Pluripotent Stem Cells | 5 | 2022 | 1736 | 0.910 |
Why?
|
| Tissue Array Analysis | 2 | 2021 | 553 | 0.840 |
Why?
|
| Biological Assay | 1 | 2021 | 652 | 0.600 |
Why?
|
| Long QT Syndrome | 1 | 2019 | 453 | 0.500 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 588 | 0.480 |
Why?
|
| Patch-Clamp Techniques | 3 | 2021 | 964 | 0.460 |
Why?
|
| Lung Transplantation | 1 | 2018 | 1155 | 0.350 |
Why?
|
| Electrophysiological Phenomena | 2 | 2021 | 315 | 0.330 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1534 | 0.300 |
Why?
|
| Hemostasis, Surgical | 1 | 2021 | 128 | 0.190 |
Why?
|
| Electrocoagulation | 1 | 2021 | 158 | 0.190 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2021 | 71 | 0.190 |
Why?
|
| Potassium Channel Blockers | 1 | 2019 | 171 | 0.170 |
Why?
|
| Glucan 1,4-alpha-Glucosidase | 1 | 2018 | 8 | 0.170 |
Why?
|
| Action Potentials | 3 | 2022 | 1806 | 0.160 |
Why?
|
| Sodium Channel Blockers | 1 | 2019 | 176 | 0.160 |
Why?
|
| Tetrodotoxin | 1 | 2019 | 259 | 0.160 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 2018 | 41 | 0.160 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2018 | 78 | 0.160 |
Why?
|
| Blood Loss, Surgical | 1 | 2021 | 662 | 0.150 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2019 | 256 | 0.140 |
Why?
|
| Neurofibromatosis 1 | 1 | 2021 | 570 | 0.140 |
Why?
|
| Cardiomegaly | 1 | 2018 | 620 | 0.130 |
Why?
|
| Living Donors | 1 | 2018 | 621 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2018 | 1851 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 944 | 0.110 |
Why?
|
| Growth Disorders | 1 | 2018 | 645 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2019 | 11486 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2021 | 19233 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 1912 | 0.070 |
Why?
|
| Calcium | 1 | 2019 | 5755 | 0.070 |
Why?
|
| Phenotype | 1 | 2019 | 16367 | 0.050 |
Why?
|
| Ion Transport | 1 | 2022 | 320 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21748 | 0.050 |
Why?
|
| Child | 2 | 2019 | 77709 | 0.050 |
Why?
|
| Humans | 8 | 2022 | 744366 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15297 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 1879 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 2716 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 56429 | 0.030 |
Why?
|
| Female | 3 | 2021 | 380193 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 85779 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 2269 | 0.020 |
Why?
|
| Male | 4 | 2021 | 350115 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 213390 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 214052 | 0.020 |
Why?
|
| Length of Stay | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 41005 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 35134 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 63107 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81201 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 168768 | 0.000 |
Why?
|